1 not yet recruiting. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Not yet recruiting 1 |
Follow Duration of Response: new trials by email Literature Review of Duration of Response trials Research Report on Duration of Response
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma SCA Induction followed by Response-Adapted Therapy - Complete Remission Rateļ¼ CRR, Progression Free Survival | Not applicable | Not yet recruiting | Sun Yat-sen University | 30 | 2026-06-01 | 2026-04-21 |
Lymphoma, Extranodal NK-T-Cell (1)
Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
China (1)